Prevalence and Thrombotic Risk Assessment of Anti-β2 Glycoprotein I Domain I Antibodies: A Systematic Review

Radin, Massimo; Cecchi, Irene; Roccatello, Dario; Meroni, Pier Luigi; Sciascia, Savino

doi:10.1055/s-0037-1603936

Cited by 63 publications

(47 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several different studies have shown a significant association of anti-D1 positivity to the risk of thrombosis, while the correlation with pregnancy morbidity was less evident [130][131][132][133][134].…”

Section: The Addition Of Anti-domain I To Laboratory Classification Cmentioning

confidence: 97%

“…Of the 25 potentially relevant publications, 15 studies have been selected for analysis. Pulling together the results of 11 papers, for a total of 1585 patients, the overall estimated median prevalence of anti-D1 antibodies was 43%, ranging from 26.7% in SLE patients to 55.4% in primary APS [130].…”

Section: Anti-β2gpi Antibodiesmentioning

confidence: 99%

“…Interestingly, anti-D1 positivity has been associated to triple aPL positivity, LA positivity and the presence of an additional autoimmune disease and higher anti-D1 titers have been observed in triple aPL positive APS patients and in patients with a history of thrombosis [130][131][132][133][134]. By contrast, only 3 studies reported the prevalence and clinical significance of anti-D4/5 autoantibodies.…”

Section: The Addition Of Anti-domain I To Laboratory Classification Cmentioning

confidence: 99%

“…Even if anti-D1 positivity has been clearly associated with the risk of thrombosis, a relevant prognostic value of this subgroup of autoantibodies for pregnancy complications is still to be confirmed [130][131][132][133][134]. In several different studies, antia higher prognostic value than anti-D1 for thrombotic events [131,136,137].…”

Section: There Is No Evidence That Anti-domain I Can Substitute Anti-mentioning

confidence: 99%

See 3 more Smart Citations

Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis

Giacomelli

Afeltra

Alunno

et al. 2019

Autoimmunity Reviews

101

View full text Add to dashboard Cite

Autoimmune rheumatic diseases are characterised by an abnormal immune system response, complement activation, cytokines dysregulation and inflammation. In last years, despite many progresses in managing these patients, it has been shown that clinical remission is reached in less than 50% of patients and a personalised and tailored therapeutic approach is still lacking resulting in a significant gap between guidelines and real-world practice. In this context, the need for biomarkers facilitating early diagnosis and profiling those individuals at the highest risk for a poor outcome has become of crucial interest. A biomarker generally refers to a measured characteristic which may be used as an indicator of some biological state or condition. Three different types of medical biomarkers has been suggested: i. mechanistic markers; ii. clinical disease markers; iii. therapeutic markers. A combination of biomarkers from these different groups could be used for an ideal more accurate diagnosis and treatment. However, although a growing body of evidence is focused on improving biomarkers, a significant amount of this information is not integrated on standard clinical care. The overarching aim of this work was to clarify the meaning of specific biomarkers during autoimmune diseases; their possible role in confirming diagnosis, predicting outcome and suggesting specific treatments.

show abstract

Section: The Addition Of Anti-domain I To Laboratory Classification Cmentioning

confidence: 97%

Section: Anti-β2gpi Antibodiesmentioning

confidence: 99%

Section: The Addition Of Anti-domain I To Laboratory Classification Cmentioning

confidence: 99%

Section: There Is No Evidence That Anti-domain I Can Substitute Anti-mentioning

confidence: 99%

See 2 more Smart Citations

Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis

Giacomelli

Afeltra

Alunno

et al. 2019

Autoimmunity Reviews

101

View full text Add to dashboard Cite

show abstract

“…13,14 Kelchtermans et al therefore provide an overview of studies on these antibodies and discuss their relevance for the pathophysiology of the syndrome, 15 and Radin et al summarize the available evidence to support their use in the diagnostic workup of patients in a systematic review. 16 How circulating aPL are linked to thrombosis and pregnancy-associated pathology remains a topic of investigation. Sacharidou et al therefore summarize the currently available data on the pathophysiology of APS.…”

mentioning

confidence: 99%

Recent Developments in Antiphospholipid Antibodies and the Antiphospholipid Syndrome

Urbanus

2018

Semin Thromb Hemost

View full text Add to dashboard Cite

Antiphospholipid Antibodies Increase Endometrial Stromal Cell Decidualization, Senescence, and Inflammation via Toll‐like Receptor 4, Reactive Oxygen Species, and p38 MAPK Signaling

Tong

Kayani

Jones

et al. 2022

Arthritis & Rheumatology

View full text Add to dashboard Cite

Objective Miscarriage affects 1 in 7 pregnancies, and antiphospholipid autoantibodies (aPLs) are one of the biggest risk factors for recurrent pregnancy loss. While aPLs target the endometrial stroma, little is known about their impact. Endometrial stromal cells (EnSCs) undergo decidualization each menstrual cycle, priming the uterus to receive implanting embryos. Thus, appropriate decidualization and EnSC function is key for establishment of a successful pregnancy. This study was undertaken to explore the effects of aPL on EnSC decidualization, senescence, and inflammation. Methods EnSCs under decidualizing conditions were exposed to aPL or control IgG alone or in the presence of either a Toll‐like receptor 4 (TLR‐4) antagonist, a p38 MAPK inhibitor, a reactive oxygen species (ROS) inhibitor, low molecular weight heparin (LMWH), or acetyl salicylic acid. Secretion of decidualization markers and inflammatory interleukin‐8 were quantified by enzyme‐linked immunosorbent assay, and senescence‐associated β‐galactosidase activity was evaluated. In a mouse model of decidualization, aPL or control IgG was administered, and uterine expression levels of decidualization and inflammatory markers were quantified by real‐time quantitative polymerase chain reaction. Results Antiphospholipid antibodies increased human EnSC decidualization, senescence, and inflammation. This phenotype was recapitulated in the mouse model. The decidualization and inflammatory responses were partially mediated by TLR‐4 and p38 MAPK, while the decidualization and senescence responses were ROS‐dependent. LMWH, commonly used to treat aPL‐positive women at risk of obstetric complications, reduced the ability of aPL to increase EnSC decidualization and inflammation. Conclusion These findings shed new light on the pathogenesis of pregnancy complications in women with aPLs and underscore the benefit of heparin in preventing pregnancy loss in this high‐risk population.

show abstract

Prevalence and Thrombotic Risk Assessment of Anti-β2 Glycoprotein I Domain I Antibodies: A Systematic Review

Cited by 63 publications

References 42 publications

Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis

Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis

Recent Developments in Antiphospholipid Antibodies and the Antiphospholipid Syndrome

Antiphospholipid Antibodies Increase Endometrial Stromal Cell Decidualization, Senescence, and Inflammation via Toll‐like Receptor 4, Reactive Oxygen Species, and p38 MAPK Signaling

Contact Info

Product

Resources

About